Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia

  title={Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia},
  author={C. E. Marx and Jimmy Lee and Mythily Subramaniam and Attilio Rapisarda and Dianne Carol Bautista and Edwin Chan and Jason D. Kilts and Robert W. Buchanan and Eu Pui Wai and Swapna Verma and Kang Sim and Jayaraman Hariram and Rajesh Abraham Jacob and Richard S. E. Keefe and Siow Ann Chong},
Preclinical and clinical data suggest that pregnenolone may be a promising therapeutic in schizophrenia. Pregnenolone is neuroprotective and enhances learning and memory, myelination, and microtubule polymerization. Treatment with pregnenolone elevates allopregnanolone (a neurosteroid that enhances GABAA receptor responses) and pregnenolone sulfate (a positive NMDA receptor modulator). Pregnenolone could thus potentially mitigate GABA dysregulation and/or NMDA receptor hypofunction in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
13 Citations
103 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 13 extracted citations


Publications referenced by this paper.
Showing 1-10 of 103 references

Multi-year continuation study of pregnenolone in patients with schizophrenia (Symposium Presentation in “Neurosteroids as Novel Therapeutics in Schizophrenia and other CNS Disorders

  • AJ Savitz
  • Society of Biological Psychiatry Annual Meeting,
  • 2010
Highly Influential
6 Excerpts

Neurosteroids as biomarker candidates and novel therapeutics in schizophrenia and bipolar depression

  • S Brown
  • Society of Biological Psychiatry Annual Meeting,
  • 2013
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…